Our discovery identifies MBL2 as an NK cell-activating cytokine, initiating the integrin β1/FAK/AKT pathway in NK cells and reshaping an immune-activated microenvironment of HCC. This evidence concerns the gene AKT1 and hepatocellular carcinoma.